EXETER, N.H.--(BUSINESS WIRE)--Dec. 12, 2005--Bentley Pharmaceuticals, Inc. (NYSE: BNT), a technology-based specialty pharmaceutical and drug delivery company with a growing branded and generic product line in Europe, announced today that it has received approvals of generic versions of its lansoprazole formulations in the UK. Product launch in the UK market will begin immediately through its licensees. Marketing approval has been granted by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the 15 mg. and 30 mg. dosage strengths of lansoprazole capsules, which will be supplied to licensees. According to industry sources, the annual market size of lansoprazole in the European Union is approximately $880 million, of which the UK accounts for approximately 45%, or approximately $400 million.
